Evidence map›Paper›PMID 39920775›Full record

ArticleMolecular neurodegeneration2025

Loss of MEF2C function by enhancer mutation leads to neuronal mitochondria dysfunction and motor deficits in mice.

Ali Yousefian-Jazi, Suhyun Kim, Jiyeon Chu, Seung-Hye Choi, Phuong Thi Thanh Nguyen, Uiyeol Park, Min-Gyeong Kim, Hongik Hwang, Kyungeun Lee, Yeyun Kim and 8 more

Abstract read
In one paragraph

Article in Molecular neurodegeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Ali Yousefian-JaziLaboratory for Brain Gene Regulation and Epigenetics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Suhyun KimLaboratory for Brain Gene Regulation and Epigenetics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Jiyeon ChuLaboratory for Brain Gene Regulation and Epigenetics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Seung-Hye ChoiSeverance Biomedical Science Institute, Graduate School of Medical Science, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Phuong Thi Thanh NguyenLaboratory for Brain Gene Regulation and Epigenetics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Uiyeol ParkLaboratory for Brain Gene Regulation and Epigenetics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Min-Gyeong KimKIST School, Division of Bio-Medical Science & Technology, University of Science and Technology (UST), Seoul, 02792, Republic of Korea.
Hongik HwangDepartment of Life Science, University of Seoul, Seoul, 02504, Republic of Korea.
Kyungeun LeeAdvanced Analysis Data Center, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Yeyun KimLaboratory for Brain Gene Regulation and Epigenetics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Seung Jae HyeonLaboratory for Brain Gene Regulation and Epigenetics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Hyewhon RhimBrain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Hannah L RyuBoston University Alzheimer's Disease Research Center and Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA.
Grewo LimBoston University Alzheimer's Disease Research Center and Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA.
Thor D SteinBoston University Alzheimer's Disease Research Center and Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA.
Kayeong LimBrain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
Hoon RyuLaboratory for Brain Gene Regulation and Epigenetics, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea. hoonryu@kist.re.kr.ORCID 0000-0001-6544-3732
Junghee LeeBoston University Alzheimer's Disease Research Center and Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA. junghee@bu.edu.

Funding

Modulation of neuronal atrophy in Huntington's diseaseR01NS109537 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LEE, JUNGHEE · 2018 to 2022
$1.4M
KIST Grant 2E30954Korea Dementia Research Project Grant HU23C0217National Research Foundation 2022R1A2C3013138NIH R01 R01NS109537NINDS NIH HHS R01 NS109537
6 · The paper itself

Abstract

backgroundAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the loss of both upper and lower motor neurons, leading to progressive paralysis. Both genetic alterations and epigenetic modifications contribute to neuronal dysfunction in the pathogenesis of ALS. However, the mechanism behind genetic mutations in the non-coding region of genes that affect epigenetic modifications remains unclear.

methodsConvolutional neural network was used to identify an ALS-associated SNP located in the intronic region of MEF2C (rs304152), residing in a putative enhancer element. To examine the alteration of MEF2C transcription by the SNP, we generated HEK293T cells carrying the major or minor allele by CRISPR-Cas9. To verify the role of MEF2C-knockdown (MEF2C-KD) in mice, we developed AAV expressing shRNA for MEF2C based on AAV-U6 promoter vector. Neuropathological alterations of MEF2C-KD mice with mitochondrial dysfunction and motor neuronal damage were observed by confocal microscopy and transmission electron microscope (TEM). Behavioral changes of mice were examined through longitudinal study by tail suspension, inverted grid test and automated gait analysis.

resultsHere, we show that enhancer mutation of MEF2C reduces own gene expression and consequently impairs mitochondrial function in motor neurons. MEF2C localizes and binds to the mitochondria DNA, and directly modulates mitochondria-encoded gene expression. CRISPR/Cas-9-induced mutation of the MEF2C enhancer decreases expression of mitochondria-encoded genes. Moreover, MEF2C mutant cells show reduction of mitochondrial membrane potential, ATP level but elevation of oxidative stress. MEF2C deficiency in the upper and lower motor neurons of mice impairs mitochondria-encoded genes, and leads to mitochondrial metabolic disruption and progressive motor behavioral deficits.

conclusionsTogether, MEF2C dysregulation by the enhancer mutation leads to mitochondrial dysfunction and oxidative stress, which are prevalent features in motor neuronal damage and ALS pathogenesis. This genetic and epigenetic crosstalk mechanism provides insights for advancing our understanding of motor neuron disease and developing effective treatments.

Indexed as

Amyotrophic Lateral SclerosisMEF2 Transcription FactorsMitochondriaMotor NeuronsAnimalsDisease Models, AnimalEnhancer Elements, GeneticHEK293 CellsHumansMiceMutationMef2c protein, mouseMEF2 Transcription FactorsEpigeneticsMEF2CMitochondriaMotor neuronSingle nucleotide polymorphism (SNP)

Identifiers

PMID39920775
PMCPMC11806887

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.